{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:57:57Z","timestamp":1790675877576,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To assess the impact of a novel molecular imaging technique,\n                      <jats:sup>68<\/jats:sup>\n                      Ga\u2010(HBED\u2010CC)\u2010prostate\u2010specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT), in the clinical management of patients with prostate cancer with rising prostate\u2010specific antigen (PSA) after treatment with curative intent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      In all, 131 consecutive patients were referred to our centre for a\n                      <jats:sup>68<\/jats:sup>\n                      Ga\u2010PSMA PET\/CT in the setting of recurring prostate cancer. Of these patients, 11\/131(8%) presented with persistent PSA after radical prostatectomy, while 120\/131 (92%) were referred for biochemical recurrence after surgery, radiotherapy or both. The images where taken 1 h after injection of 2 MBq\/kg of the\n                      <jats:sup>68<\/jats:sup>\n                      Ga\u2010(HBED\u2010CC)\u2010PSMA ligand. All examinations were interpreted by two experienced nuclear medicine specialists. Using the results of the examination, a multidisciplinary oncology committee (MOC) reported on the treatment strategy. A positive impact on clinical management was considered if the examination determined a modification in the treatment strategy compared to the MOC decision before PSMA imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All patients completed the examination with no adverse reactions. The median (interquartile range) PSA level at the time of the examination was 2.2 (0.72\u20136.7) ng\/mL. Overall,\n                      <jats:sup>68<\/jats:sup>\n                      Ga\u2010PSMA PET\/CT detected at least one lesion suspicious for prostate cancer in 98\/131 (75%) patients. There was an impact on subsequent management in 99\/131 patients (76%). The main modifications included continuing surveillance (withholding hormonal therapy), hormonal manipulations, stereotaxic radiotherapy, salvage radiotherapy, salvage node dissection or salvage local treatment (prostatectomy, high\u2010intensity focussed ultrasound).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our preliminary experience suggests that performing\n                      <jats:sup>68<\/jats:sup>\n                      Ga\u2010PSMA PET\/CT in patients with prostate cancer with rising PSA after treatment with curative intent can be clinically useful as it changes the treatment strategy in a significant proportion of patients. However, larger prospective trials are needed to validate our present findings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13739","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T07:22:14Z","timestamp":1481959334000},"page":"197-203","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Clinical impact of\n                    <sup>68<\/sup>\n                    Ga\u2010prostate\u2010specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) in patients with prostate cancer with rising prostate\u2010specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach"],"prefix":"10.1111","volume":"120","author":[{"given":"Simone","family":"Albisinni","sequence":"first","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Artigas","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Aoun","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Biaou","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Grosman","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Oncology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hawaux","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Limani","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois\u2010Xavier","family":"Otte","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Peltier","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Sideris","sequence":"additional","affiliation":[{"name":"Department of Oncology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sirtaine","sequence":"additional","affiliation":[{"name":"Department ofPathology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"van Velthoven","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Jules Bordet Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.023"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2009.10.015"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0675"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13397"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3240-1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-008-9104-2"},{"key":"e_1_2_9_11_1","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz JS","year":"1987","journal-title":"Anticancer Res"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3490-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.172627"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2012.10.090"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4655"},{"key":"e_1_2_9_17_1","first-page":"501213","article-title":"A comprehensive review of contemporary role of local treatment of the primary tumor and\/or the metastases in metastatic prostate cancer","volume":"2014","author":"Aoun F","year":"2014","journal-title":"Bio Med Res Int"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.104"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.3000"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-016-0646-2"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.160382"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.173492"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3106-6"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2949-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.154153"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.179237"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001264"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3236-x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3435-0"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3302-4"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3078-6"},{"key":"e_1_2_9_32_1","first-page":"6357","article-title":"Correlation of primary tumor prostate\u2010specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross JS","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-015-0548-8"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.09.004"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:20:41Z","timestamp":1761744041000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/bju.13739"],"URL":"https:\/\/doi.org\/10.1111\/bju.13739","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,4]]},"assertion":[{"value":"2017-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}